HomeCompareAMGN vs ACN

AMGN vs ACN: Dividend Comparison 2026

AMGN yields 2.77% · ACN yields 3.30%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ACN wins by $45.17M in total portfolio value
10 years
AMGN
AMGN
● Live price
2.77%
Share price
$349.00
Annual div
$9.66
5Y div CAGR
48.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$164.2K
Annual income
$69,743.86
Full AMGN calculator →
ACN
ACN
● Live price
3.30%
Share price
$197.55
Annual div
$6.52
5Y div CAGR
85.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$45.34M
Annual income
$40,254,140.02
Full ACN calculator →

Portfolio growth — AMGN vs ACN

📍 ACN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAMGNACN
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AMGN + ACN cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AMGN pays
ACN pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AMGN
Annual income on $10K today (after 15% tax)
$235.27/yr
After 10yr DRIP, annual income (after tax)
$59,282.28/yr
ACN
Annual income on $10K today (after 15% tax)
$280.54/yr
After 10yr DRIP, annual income (after tax)
$34,216,019.02/yr
At 15% tax rate, ACN beats the other by $34,156,736.74/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AMGN + ACN for your $10,000?

AMGN: 50%ACN: 50%
100% ACN50/50100% AMGN
Portfolio after 10yr
$22.75M
Annual income
$20,161,941.94/yr
Blended yield
88.62%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ACN right now

AMGN
Analyst Ratings
22
Buy
13
Hold
3
Sell
Consensus: Buy
Price Target
$347.73
-0.4% upside vs current
Range: $185.00 — $432.00
Altman Z
2.3
Piotroski
8/9
ACN
Analyst Ratings
39
Buy
13
Hold
1
Sell
Consensus: Buy
Price Target
$299.92
+51.8% upside vs current
Range: $265.00 — $330.00
Altman Z
4.3
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AMGN buys
0
ACN buys
0
No recent congressional trades found for AMGN or ACN in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAMGNACN
Forward yield2.77%3.30%
Annual dividend / share$9.66$6.52
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR48.6%85.1%
Portfolio after 10y$164.2K$45.34M
Annual income after 10y$69,743.86$40,254,140.02
Total dividends collected$133.8K$44.91M
Payment frequencyquarterlyquarterly
SectorHealthcareTechnology
Analyst consensusBuyBuy
Analyst price target$347.73$299.92

Year-by-year: AMGN vs ACN ($10,000, DRIP)

YearAMGN PortfolioAMGN Income/yrACN PortfolioACN Income/yrGap
1← crossover$11,111$411.31$11,311$610.91$200.00ACN
2$12,524$634.70$13,298$1,195.36$774.00ACN
3$14,394$993.52$16,660$2,431.14$2.3KACN
4$16,987$1,585.83$23,095$5,268.91$6.1KACN
5$20,776$2,599.19$37,347$12,635.37$16.6KACN
6$26,645$4,414.70$75,308$35,346.62$48.7KACN
7$36,373$7,863.06$203,877$123,297.57$167.5KACN
8$53,826$14,907.12$795,585$577,436.45$741.8KACN
9$88,231$30,636.84$4,749,302$3,898,026.13$4.66MACN
10$164,151$69,743.86$45,335,893$40,254,140.02$45.17MACN

AMGN vs ACN: Complete Analysis 2026

AMGNHealthcare

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Full AMGN Calculator →

ACNTechnology

Accenture plc, a professional services company, provides strategy and consulting, interactive, and technology and operations services worldwide. The company offers application services, including agile transformation, DevOps, application modernization, enterprise architecture, software and quality engineering, data management, intelligent automation comprises robotic process automation, natural language processing, and virtual agents, and liquid application management services, as well as program, project, and service management services; strategy consulting services; critical data elements, data management and governance, data platform and architecture, product-based organization and skills, business adoption, and value realization services; engineering, and research and development digitization; smart connected product design and development; product platform engineering and modernization; product as-a-service enablement; products related to production and operations; autonomous robotics systems; the digital transformation of capital projects; and digital industrial workforce solutions. It also provides data-enabled operating models; technology consulting and artificial intelligence services; services related to talent and organization/human potential; digital commerce; infrastructure services, such as hybrid cloud, network, digital workplace and collaboration, service and experience management, infrastructure as code, and managed edge and IoT devices; cyber defense, applied cybersecurity, managed security, OT security, security strategy and risk, and industry security products; services related to technology innovation; and intelligent automation services. In addition, the company offers cloud, ecosystem, marketing, supply chain management, zero-based budgeting, customer experience, finance consulting, mergers and acquisitions, and sustainability services. Accenture plc was founded in 1951 and is based in Dublin, Ireland.

Full ACN Calculator →
📬

Get this AMGN vs ACN comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AMGN vs SCHDAMGN vs JEPIAMGN vs OAMGN vs KOAMGN vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.